Biosplice Therapeutics Statistics and Revenue Totals (2023)
Last Updated on: August 3rd, 2022
Here are a few of the most interesting Biosplice Therapeutics statistics I was able to dig up including Biosplice Therapeutics revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Biosplice Therapeutics Facts
- Website: Official Website
- Year Founded: 2008
- Headquarters: San Diego, CA
- Founder(s): Osman Kibar
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center. Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions. (source)
Biosplice Therapeutics Statistics
Additional Biosplice Therapeutics Statistics
Nothing to report just yet. Be sure to check back soon for updates.
Please note that some of these numbers are easier to find than others. A few of these Biosplice Therapeutics statistics come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.